Evidence map›Paper›PMID 30781802›Full record

ReviewInternational journal of molecular sciences2019

Sleep Disturbance as a Potential Modifiable Risk Factor for Alzheimer's Disease.

Eiko N Minakawa, Keiji Wada, Yoshitaka Nagai

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 2 pooled it
6.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 2 syntheses or guidelines pooled it, 118 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Home-Based Tailored Light Therapy for Sleep, Mood, and Cognitive Outcomes in Mild Cognitive Impairment: A Randomized Trial.Journal of applied gerontology : the official journal of the Southern Gerontological Society · 2026
    Article
  8. Review
  9. Zolpidem restores sleep and decreases amyloid in a mouse model.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  10. Article
  11. Review
  12. Article
  13. Psychiatric Risk Factors for Progression From Mild Cognitive Impairment to Alzheimer's Disease: A Systematic Review.The American journal of geriatric psychiatry. Open science, education, and practice · 2025
    Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Chronic chemogenetic slow-wave-sleep enhancement in mice.bioRxiv : the preprint server for biology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Eiko N MinakawaDepartment of Degenerative Neurological Diseases, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira 187-8502, Japan. minakawa@ncnp.go.jp.
Keiji WadaDepartment of Degenerative Neurological Diseases, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira 187-8502, Japan. wada@ncnp.go.jp.
Yoshitaka NagaiDepartment of Degenerative Neurological Diseases, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira 187-8502, Japan. nagai@neurother.med.osaka-u.ac.jp.ORCID 0000-0003-1037-3129
National Center of Neurology and Psychiatry · JP

Funding

Japan Agency for Medical Research and Development JP16ek0109018Japan Agency for Medical Research and Development JP18ek0109222Japan Foundation for Neuroscience and Mental Health 2017Japan Society for the Promotion of Science 18H02585Japan Society for the Promotion of Science 18K15474Japan Society for the Promotion of Science 26860681National Center of Neurology and Psychiatry 27-9National Center of Neurology and Psychiatry 30-3
6 · The paper itself

Abstract

Sleep disturbance is a common symptom in patients with various neurodegenerative diseases, including Alzheimer's disease (AD), and it can manifest in the early stages of the disease. Impaired sleep in patients with AD has been attributed to AD pathology that affects brain regions regulating the sleep⁻wake or circadian rhythm. However, recent epidemiological and experimental studies have demonstrated an association between impaired sleep and an increased risk of AD. These studies have led to the idea of a bidirectional relationship between AD and impaired sleep; in addition to the conventional concept that impaired sleep is a consequence of AD pathology, various evidence strongly suggests that impaired sleep is a risk factor for the initiation and progression of AD. Despite this recent progress, much remains to be elucidated in order to establish the benefit of therapeutic interventions against impaired sleep to prevent or alleviate the disease course of AD. In this review, we provide an overview of previous studies that have linked AD and sleep. We then highlight the studies that have tested the causal relationship between impaired sleep and AD and will discuss the molecular and cellular mechanisms underlying this link. We also propose future works that will aid the development of a novel disease-modifying therapy and prevention of AD via targeting impaired sleep through non-pharmacological and pharmacological interventions.

Indexed as

AgingAlzheimer DiseaseHumansNerve NetProteostasisRisk FactorsSleep Wake DisordersAlzheimer’s diseaseamyloid betacognitive behavioral therapy for insomniadefault-mode networkproteostasissleep disturbancesleep fragmentationslow-wave sleeptau

Identifiers

PMID30781802
PMCPMC6412395
OpenAlexW2913067573

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.